$CLSD
Clearside Biomedical, Inc. Stock $clsd

$clsd Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000095017022023525 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$330.0K	$266.0K	$3.074M
YoY Change	-98.72%	-91.35%	-10.43%
Cost Of Revenue	$204.0K	$0.00
YoY Change
Gross Profit	$126.0K	$266.0K
YoY Change
Gross Profit Margin	38.18%	100.0%
Selling, General & Admin	$3.169M	$2.353M	$2.816M
YoY Change	0.92%	-16.44%	18.82%
% of Gross Profit	2515.08%	884.59%
Research & Development	$5.027M	$4.637M	$5.147M
YoY Change	30.91%	-9.91%	47.48%
% of Gross Profit	3989.68%	1743.23%
Depreciation & Amortization	$22.00K	$39.00K	$44.00K
YoY Change	-51.11%	-11.36%	-12.0%
% of Gross Profit	17.46%	14.66%
Operating Expenses	$8.196M	$6.990M	$7.963M
YoY Change	17.42%	-12.22%	35.79%
Operating Profit	-$8.070M	-$6.724M	-$4.889M
YoY Change		37.53%	101.03%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$2.042M	-$1.297M	$0.00
YoY Change
Pretax Income	-$9.663M	-$7.827M	-$4.887M
YoY Change	-151.65%	60.16%	101.11%
Income Tax
% Of Pretax Income
Net Earnings	-$9.663M	-$7.827M	-$4.887M
YoY Change	-151.65%	60.16%	100.86%
Net Earnings / Revenue	-2928.18%	-2942.48%	-158.98%
Basic Earnings Per Share		-$0.13	-$0.08
Diluted Earnings Per Share	-$0.16	-$0.13	-$82.17K
COMMON SHARES
Basic Shares Outstanding	60.19M	60.19M	59.48M
Diluted Shares Outstanding		60.19M	59.47M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$48.26M	$53.38M	$25.22M
YoY Change	58.56%	111.69%	70.39%
Cash & Equivalents	$48.30M	$53.40M	$25.20M
Short-Term Investments
Other Short-Term Assets	$439.0K	$311.0K	$119.0K
YoY Change	-43.65%	161.34%	-90.08%
Inventory
Prepaid Expenses	$704.0K	$1.047M	$1.187M
Receivables	$0.00	$123.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$49.40M	$54.86M	$26.52M
YoY Change	17.24%	106.85%	65.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$755.0K	$437.0K	$283.0K
YoY Change	217.23%	54.42%	-71.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$30.00K	$160.0K	$160.0K
YoY Change	-81.25%	0.0%	-60.0%
Total Long-Term Assets	$1.902M	$823.0K	$855.0K
YoY Change	147.98%	-3.74%	-38.93%
TOTAL ASSETS
Total Short-Term Assets	$49.40M	$54.86M	$26.52M
Total Long-Term Assets	$1.902M	$823.0K	$855.0K
Total Assets	$51.30M	$55.69M	$27.38M
YoY Change	19.58%	103.39%	57.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.050M	$1.739M	$776.0K
YoY Change	11.58%	124.1%	-13.78%
Accrued Expenses	$4.179M	$2.945M	$2.996M
YoY Change	26.18%	-1.7%	76.24%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$5.783M	$5.204M	$9.156M
YoY Change	24.63%	-43.16%	11.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$34.91M	$31.94M	$374.0K
YoY Change	12022.57%	8438.77%	-46.57%
Total Long-Term Liabilities	$34.91M	$31.94M	$374.0K
YoY Change	12022.57%	8438.77%	-66.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.783M	$5.204M	$9.156M
Total Long-Term Liabilities	$34.91M	$31.94M	$374.0K
Total Liabilities	$40.70M	$37.14M	$9.530M
YoY Change	725.81%	289.71%	2.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$288.4M	-$278.8M	-$274.2M
YoY Change	12.9%	1.67%
Common Stock	$61.00K	$60.00K	$60.00K
YoY Change	1.67%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.61M	$18.55M	$17.85M
YoY Change
Total Liabilities & Shareholders Equity	$51.30M	$55.69M	$27.38M
YoY Change	19.58%	103.39%	57.34%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$9.663M	-$7.827M	-$4.887M
YoY Change	-151.65%	60.16%	100.86%
Depreciation, Depletion And Amortization	$22.00K	$39.00K	$44.00K
YoY Change	-51.11%	-11.36%	-12.0%
Cash From Operating Activities	-$5.607M	-$6.186M	-$3.278M
YoY Change	-210.94%	88.71%	23.23%
INVESTING ACTIVITIES
Capital Expenditures	$91.00K	-$155.0K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$91.00K	-$155.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	575.0K	30.69M	2.081M
YoY Change	248.48%	1374.72%	-14.36%
NET CHANGE
Cash From Operating Activities	-5.607M	-6.186M	-3.278M
Cash From Investing Activities	-91.00K	-155.0K	0.000
Cash From Financing Activities	575.0K	30.69M	2.081M
Net Change In Cash	-5.123M	24.35M	-1.197M
YoY Change	-198.16%	-2134.09%	420.43%
FREE CASH FLOW
Cash From Operating Activities	-$5.607M	-$6.186M	-$3.278M
Capital Expenditures	$91.00K	-$155.0K	$0.00
Free Cash Flow	-$5.698M	-$6.031M	-$3.278M
YoY Change	-212.74%	83.98%	23.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	City Area Code CityAreaCode	678
	dei	Local Phone Number LocalPhoneNumber	270-3631
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	CLSD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	111000
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60190731
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53381000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30436000
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	123000
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	10000000
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1047000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	921000
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	311000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	779000
	dei	Document Type DocumentType	10-Q
CY2022Q3	us-gaap	Assets Current AssetsCurrent	54862000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt
	clsd	Net Proceeds After Deducting Offering Expenses NetProceedsAfterDeductingOfferingExpenses
	clsd	Proceeds From Royalty Purchase And Sale Agreement Net Of Issuance Costs ProceedsFromRoyaltyPurchaseAndSaleAgreementNetOfIssuanceCosts
	clsd	Forgiveness Of Paycheck Protection Program Loan And Accrued Interest ForgivenessOfPaycheckProtectionProgramLoanAndAccruedInterest
CY2022Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	clsd	Proceeds From Issuance At The Market ProceedsFromIssuanceAtTheMarket
CY2021Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment
CY2021Q3	us-gaap	Restricted Cash Asset Statement Of Financial Position Extensible List RestrictedCashAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsCurrent
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent
	clsd	Non Cash Interest Expense On Liability Related To The Sales Of Future Royalites NonCashInterestExpenseOnLiabilityRelatedToTheSalesOfFutureRoyalites
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001539029
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities
CY2021Q4	us-gaap	Assets Current AssetsCurrent	42136000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	437000
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	238000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	226000
	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	369000
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	160000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	160000
	dei	Entity File Number EntityFileNumber	001-37783
CY2022Q3	us-gaap	Assets Assets	55685000
CY2021Q4	us-gaap	Assets Assets	42903000
	dei	Entity Registrant Name EntityRegistrantName	Clearside Biomedical, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	288000
CY2022Q3	us-gaap	Liabilities Liabilities	37139000
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2437375
	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 North Point Parkway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Alpharetta
	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30005
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1739000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	941000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2945000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3312000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	407000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	387000
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	113000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5204000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4640000
CY2022Q3	clsd	Liabilities Related To The Sales Of Future Royalties LiabilitiesRelatedToTheSalesOfFutureRoyalties	31935000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14697000
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2353000
CY2021Q4	us-gaap	Liabilities Liabilities	4928000
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	194000
CY2021Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2000
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60190731
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60190731
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59722930
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59722930
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	60000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	60000
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	297261000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	293406000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-278775000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-255491000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	18546000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	37975000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55685000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42903000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	266000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3074000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	997000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3888000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4637000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5147000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14603000
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2816000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8601000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8525000
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	6990000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	7963000
	us-gaap	Operating Expenses OperatingExpenses	23204000
	us-gaap	Operating Expenses OperatingExpenses	23222000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6724000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4889000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22207000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19334000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7644000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	31703000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1354000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	220000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1001000
CY2022Q3	clsd	Non Cash Interest Expense On Liability Related To Sales Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSalesOfFutureRoyalties	-1297000
CY2021Q3	clsd	Non Cash Interest Expense On Liability Related To Sales Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSalesOfFutureRoyalties	0
	clsd	Non Cash Interest Expense On Liability Related To Sales Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSalesOfFutureRoyalties	-1297000
	clsd	Non Cash Interest Expense On Liability Related To Sales Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSalesOfFutureRoyalties	0
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7827000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4887000
	us-gaap	Net Income Loss NetIncomeLoss	-23284000
	us-gaap	Net Income Loss NetIncomeLoss	-18333000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60188541
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60188541
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59474346
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59474346
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60134821
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60134821
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58095080
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58095080
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	37975000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	62000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1307000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-7813000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	25248000
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	51000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1074000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7827000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	18546000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	8763000
CY2021Q1	clsd	Issuance Of Common Shares Value Under A Direct Registered Offering IssuanceOfCommonSharesValueUnderADirectRegisteredOffering	11078000
CY2021Q1	clsd	Stock Issued During Period Value At Market Sales Agreement StockIssuedDuringPeriodValueAtMarketSalesAgreement	3249000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	38000
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	54000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1154000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7351000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	16985000
CY2021Q2	clsd	Stock Issued During Period Value At Market Sales Agreement StockIssuedDuringPeriodValueAtMarketSalesAgreement	7084000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	113000
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	100000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1331000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6095000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	19338000
CY2021Q3	clsd	Stock Issued During Period Value At Market Sales Agreement StockIssuedDuringPeriodValueAtMarketSalesAgreement	1875000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	149000
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	57000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1316000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4887000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	17848000
	us-gaap	Profit Loss ProfitLoss	-23284000
	us-gaap	Profit Loss ProfitLoss	-18333000
	clsd	Non Cash Interest Expense On Liability Related To The Sales Of Future Royalites NonCashInterestExpenseOnLiabilityRelatedToTheSalesOfFutureRoyalites	1297000
	us-gaap	Depreciation Depreciation	123000
	us-gaap	Depreciation Depreciation	133000
	us-gaap	Share Based Compensation ShareBasedCompensation	3735000
	us-gaap	Share Based Compensation ShareBasedCompensation	3801000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	998000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9952000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	475000
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	125000
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	115000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	431000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	200000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	113000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7758000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15787000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	155000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-155000
	clsd	Royalty Purchase And Sale Agreement Issuance Costs RoyaltyPurchaseAndSaleAgreementIssuanceCosts	1900000
	clsd	Proceeds From Royalty Purchase And Sale Agreement Net Of Issuance Costs ProceedsFromRoyaltyPurchaseAndSaleAgreementNetOfIssuanceCosts	-30638000
	clsd	Net Proceeds After Deducting Offering Expenses NetProceedsAfterDeductingOfferingExpenses	-11078000
	clsd	Proceeds From Issuance At The Market ProceedsFromIssuanceAtTheMarket	12208000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	220000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30758000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23617000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22845000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7830000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30696000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17647000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	53541000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25477000
	clsd	Forgiveness Of Paycheck Protection Program Loan And Accrued Interest ForgivenessOfPaycheckProtectionProgramLoanAndAccruedInterest	998000
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53381000
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25217000
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	160000
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	260000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	53541000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25477000
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2011-05-26
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53400000
CY2022Q3	clsd	Initial Proceeds From Royalty Sale And Purchase Agreement Net Of Certain Expenses InitialProceedsFromRoyaltySaleAndPurchaseAgreementNetOfCertainExpenses	32100000
	clsd	Initial Proceeds From Royalty Purchase And Sale Agreement InitialProceedsFromRoyaltyPurchaseAndSaleAgreement	32500000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include revenue recognition, the accounting for useful lives to calculate depreciation and amortization, clinical trial expense accruals, share-based compensation expense, income tax valuation allowance and the liability related to the sales of future royalties. Actual results could differ from these estimates.</span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk Arising From Cash Deposits in Excess of Insured Limits</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company maintains its cash in bank deposits that at times may exceed federally insured limits. The Company has not experienced any loss in such accounts. The Company believes it is not exposed to any significant risks with respect to its cash balances.</span></p>
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	30000
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	200000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	345000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2945000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3312000
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1515000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1193000
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1078000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	955000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	437000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	238000
	clsd	Initial Proceeds From Royalty Purchase And Sales Agreement InitialProceedsFromRoyaltyPurchaseAndSalesAgreement	32500000
CY2022Q3	clsd	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	1453000
CY2021Q4	clsd	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	1083000
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1249000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1854000
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	43000
	clsd	Purchase And Sale Agreement Description PurchaseAndSaleAgreementDescription	The Purchase and Sale Agreement will automatically expire, and the payment of Royalties from the Royalty Sub to HCR will cease, when HCR has received payments of the Royalties equal to 2.5 times the aggregate amount of payments made by HCR under the Agreement if the Second Milestone Event is achieved on or prior to December 31, 2024 (the “Initial Cap”). If the Second Milestone Event is not achieved on or prior to December 31, 2024, payment of Royalties from Royalty Sub to HCR will cease when HCR has received Royalties payments equal to 3.4 times the aggregate amount of payments under the Purchase and Sale Agreement (the “Alternative Cap”, and together with the Initial Cap, the “Cap Amount”). In the event of a change in control, acquiror will have the option to make a payment to HCR of the Cap Amount then in effect, less the aggregate amount of Royalty payments made by Royalty Sub to HCR under the Purchase and Sale Agreement as a one-time payment at which time, payment of Royalties to HCR will cease. Alternatively, in the event of a change in control, the acquiror will have the option to make an initial payment of 1.0 times the aggregate amount of payments made by HCR under the Purchase and Sale Agreement as of the date of such change in control, then in that event, payment of Royalties from Royalty Sub to HCR will cease when HCR has received total Royalties payments (including the initial payment) equal to the Alternative Cap. After the Purchase and Sale Agreement expires, all rights to receive the Royalties return to Royalty Sub.
	clsd	Debt Related Commitment Fees And Debt Related Issuance Costs DebtRelatedCommitmentFeesAndDebtRelatedIssuanceCosts	1900000
	clsd	Initial Proceeds From Royalty Purchase And Sale Agreement InitialProceedsFromRoyaltyPurchaseAndSaleAgreement	32500000
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	1862000
	clsd	Non Cash Interest Expense On Liability Related To The Sales Of Future Royalites NonCashInterestExpenseOnLiabilityRelatedToTheSalesOfFutureRoyalites	1297000
CY2022Q3	clsd	Liabilities Related To The Sales Of Future Royalties LiabilitiesRelatedToTheSalesOfFutureRoyalties	31935000
CY2022Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.265
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60190731
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59722930
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	24000
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	24000
	us-gaap	Variable Lease Cost VariableLeaseCost	71000
	us-gaap	Variable Lease Cost VariableLeaseCost	71000
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	21000
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	64000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	6000
	us-gaap	Operating Lease Payments OperatingLeasePayments	305000
	us-gaap	Operating Lease Payments OperatingLeasePayments	293000
	clsd	Schedule Of Operating Leases Assets And Liabilities ScheduleOfOperatingLeasesAssetsAndLiabilities	<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company’s operating leases included on the consolidated balance sheet are as follows (in thousands):</span> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.614%;"/> <td style="width:1.948%;"/> <td style="width:1.0%;"/> <td style="width:15.438%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Operating lease right-of-use asset</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">226</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">407</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Operating lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Total operating lease liabilities</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">407</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"/> </p></td> </tr> </table>
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	226000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	407000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	407000
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	The renewal option is not included in the calculation of the right-of-use asset and the lease liabilities as the Company is renewing the current lease on to-be-determined terms.
CY2022Q3	clsd	Incremental Borrowing Rate IncrementalBorrowingRate	0.110
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2022Q3	clsd	Operating Lease Future Minimum Payment Remainder Of Fiscal Year OperatingLeaseFutureMinimumPaymentRemainderOfFiscalYear	103000
CY2022Q3	clsd	Operating Lease Future Minimum Payment Due In Two Years OperatingLeaseFutureMinimumPaymentDueInTwoYears	316000
CY2022Q3	clsd	Operating Leases Future Minimum Payment Due OperatingLeasesFutureMinimumPaymentDue	419000
CY2022Q3	clsd	Operating Lease Imputed Interest OperatingLeaseImputedInterest	12000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	407000
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	62000
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	62000
	us-gaap	Operating Lease Cost OperatingLeaseCost	185000
	us-gaap	Operating Lease Cost OperatingLeaseCost	185000
CY2022Q3	clsd	Fair Value Assets Between Level1 Level2 And Level3 Transfers Amount FairValueAssetsBetweenLevel1Level2AndLevel3TransfersAmount	0
CY2021Q4	clsd	Fair Value Assets Between Level1 Level2 And Level3 Transfers Amount FairValueAssetsBetweenLevel1Level2AndLevel3TransfersAmount	0
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8711333
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8711333
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7205882
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7205882

Files In Submission

Name	View Source	Status
0000950170-22-023525-index-headers.html	Edgar Link	pending
0000950170-22-023525-index.html	Edgar Link	pending
0000950170-22-023525.txt	Edgar Link	pending
0000950170-22-023525-xbrl.zip	Edgar Link	pending
clsd-20220930.htm	Edgar Link	pending
clsd-20220930.xsd	Edgar Link	pending
clsd-ex10_1.htm	Edgar Link	pending
clsd-ex31_1.htm	Edgar Link	pending
clsd-ex31_2.htm	Edgar Link	pending
clsd-ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img140557335_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
clsd-20220930_def.xml	Edgar Link	unprocessable
clsd-20220930_lab.xml	Edgar Link	unprocessable
clsd-20220930_cal.xml	Edgar Link	unprocessable
clsd-20220930_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
clsd-20220930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLSD
Clearside Biomedical, Inc. Stock $clsd

2022 Q4 Form 10-Q Financial Statement

#000095017022023525 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLSD Clearside Biomedical, Inc. Stock $clsd

2022 Q4 Form 10-Q Financial Statement

#000095017022023525 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLSD
Clearside Biomedical, Inc. Stock $clsd